10.6084/m9.figshare.11376051.v1 Asaoka Y. Asaoka Y. Tateishi R. Tateishi R. Hayashi A. Hayashi A. Ushiku T. Ushiku T. Shibahara J. Shibahara J. Kinoshita J. Kinoshita J. Ouchi Y. Ouchi Y. Koike M. Koike M. Fukayama M. Fukayama M. Shiina S. Shiina S. Koike K. Koike K. Supplementary Material for: Expression of c-Met in Primary and Recurrent Hepatocellular Carcinoma Karger Publishers 2019 Hepatocellular carcinoma c-Met Clinical course Prognosis 2019-12-17 07:23:59 Dataset https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Expression_of_c-Met_in_Primary_and_Recurrent_Hepatocellular_Carcinoma/11376051 <b><i>Background:</i></b>The clinical course of hepatocellular carcinoma (HCC) is complicated, because it often recurs and shows multiple lesions, some of which progress to a more malignant form, shortening the life of the patient. The hepatocyte growth factor receptor c-Met has been shown to play an important role in the pathogenesis of HCC, but the influence of c-Met expression on the clinical course of HCC remains to be fully elucidated. <b><i>Methods:</i></b>We randomly selected and included 600 tumor specimens obtained from the primary and recurrent lesions of 319 HCC cases between 1995 and 2007. The expression of c-Met was determined by immunohistochemistry using archived formalin-fixed paraffin-embedded samples. We analyzed the correlation between c-Met expression and clinical parameters, including survival. In addition, we examined c-Met expression in the malignant transition of HCC in all cases including recurrent lesions. <b><i>Results:</i></b>Survival analysis using the multivariate Cox proportional-regression model revealed that the prognosis was significantly better in the primary cases with high c-Met expression than in those with low c-Met expression (hazard ratio 0.159, 95% confidence interval 0.065–0.391; <i>p</i> < 0.001). During the course of recurrence, some cases with high c-Met expression returned to low c-Met expression. Among 40 cases with high c-Met expression, 29 survived more than 2 years after detecting the high c-Met expression. <b><i>Conclusion:</i></b>High expression of c-Met may be a prognostic factor for a good, rather than a poor, HCC prognosis. The involvement of c-Met expression in the malignant transition of recurrent HCC is obscure.